The Disease
Dengue is the world's fastest-growing mosquito-borne viral disease — and one of the most underserved therapeutic areas in infectious disease.
Global Burden
Dengue fever is caused by a flavivirus transmitted primarily through the bite of Aedes aegypti mosquitoes. It is endemic across tropical and subtropical regions spanning Asia-Pacific, Latin America, the Caribbean, Africa, and parts of the Middle East.
The global incidence of dengue has grown dramatically in recent decades — driven by urbanisation, climate change extending the range of the mosquito vector, and increased international travel. The WHO regards dengue as one of the world's most significant and rapidly expanding public health threats.
Disease Biology
Dengue is caused by four antigenically distinct serotypes (DENV-1 through DENV-4). Infection with one serotype confers long-term immunity to that serotype, but subsequent infection with a different serotype significantly increases the risk of severe dengue — characterised by plasma leakage, haemorrhage, and organ impairment.
This immunological dynamic substantially complicates both vaccine development and clinical management, and underscores the importance of effective antiviral therapy applicable across all serotypes and at all stages of infection.
| Serotype | Distribution | Clinical Notes |
|---|---|---|
| DENV-1 | Globally distributed | Primary driver of large epidemic waves; high transmission efficiency |
| DENV-2 | Americas, Asia-Pacific | Associated with higher rates of severe disease on secondary infection |
| DENV-3 | Asia, Africa, Americas | Major contributor to recent epidemic resurgences in endemic regions |
| DENV-4 | Asia, Pacific islands | Historically lower prevalence; increasingly reported across dengue-endemic regions |
Transmission & Pathology
Unmet Medical Need
Despite dengue affecting hundreds of millions of people annually, the disease remains without a specific approved antiviral therapy. Treatment guidelines across endemic markets rely entirely on supportive care — hydration, pain management, and clinical monitoring. For severe dengue, hospitalisation is required, placing substantial pressure on healthcare systems in high-burden regions.
The absence of an approved antiviral is not a reflection of low clinical priority — it reflects the scientific and regulatory complexity of developing a treatment effective across all four serotypes and across the spectrum of disease severity. This is the gap Aedion's VMD55 programme is designed to address.
Priority Markets
Dengue is most prevalent across tropical and subtropical regions, with the highest burdens concentrated in South and Southeast Asia, Latin America, and the Western Pacific. These markets represent both the greatest unmet need and the most compelling near-term regulatory and commercial opportunity for an approved antiviral.
Aedion's development strategy is designed to begin in priority endemic markets while maintaining globally credible regulatory and quality standards — establishing a pathway that supports eventual international expansion.
Learn how Aedion's globally structured development programme is targeting this unmet need.